Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 ...

Germany's largest pharma company, today reported a currency-adjusted 6.1% gain in full-year 2024 revenues, buoyed by its ...

Jardiance may cause mild side effects other than those listed above. See the drug’s prescribing information for details. Jardiance may cause serious side effects. The following list may not ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices following the expiration of Boehringer Ingelheims patent. Mankind ...

The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...

Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug across the spectrum of patients with ...

The National Pharmaceutical Pricing Authority (NPPA) has fixed prices of 80 new drugs including anti-diabetes, anti-hypertension, pain relief formulations from major pharmaceutical companies, in its ...

OK, I know my gig is positivity and being upbeat and all that, but for today I thought I’d rant on about something that irks ...

Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...